Rahul Gosain, MD

The panel presents the latest safety and efficacy updates from the IMbrave 150 trial.

The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.

Medical experts specializing in hepatocellular carcinoma (HCC) provide a detailed analysis of the IMbrave 150 study design.

Jorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.

The Oncology Brothers and Jorge Cortes, MD, discuss treatment practices for patients with accelerated phase chronic myeloid leukemia.

An expert on chronic myeloid leukemia provides clinical insights on treatment practices following progression.

A hematologist-oncologist and the Oncology Brothers outline treatment paradigms for chronic phase CML and discuss patient monitoring practices.

Jorge Cortes, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss patient workup and risk stratification practices in chronic myeloid leukemia (CML).

Pallawi Torka, MD, and the Oncology Brothers discuss the therapeutic landscape for patients with relapsed/refractory mantle cell lymphoma.

A hematologist-oncologist provides comprehensive insights on the treatment of newly diagnosed patients with mantle cell lymphoma.

The Oncology Brothers and Pallawi Torka, MD, review treatment options for patients with relapsed/refractory follicular lymphoma.

Pallawi Torka, MD, joins the Oncology Brothers to discuss patient workup and treatment practices in follicular lymphoma, highlighting the PRIMA study and the role of maintenance therapy.

Medical oncologists conclude their discussion with a review of the toxicity profiles of treatments for diffuse large B-cell lymphoma.

Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.

The Oncology Brothers and Carla Casulo, MD, discuss treatment practices for patients with stage III or IV diffuse large B-cell lymphoma.

A hematologist-oncologist joins the Oncology Brothers do discuss first-line treatment practices for patients with stage I or II diffuse large B-cell lymphoma.

Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).

Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.

Medical oncologists provide comprehensive insights on neoadjuvant therapy options for patients with melanoma.

Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.

Patrick Forde, MBBCh, and the Oncology Brothers discuss treatment practices for patients with unresectable non–small cell lung cancer.

Medical oncologists share expert perspectives on treatment paradigms for patients with early-stage NSCLC and actionable mutations.

The Oncology Brothers and Patrick Forde, MBBCh, outline immunotherapy options for patients with non–small cell lung cancer and the role of PD-L1 in informing treatment decisions.

Patrick Forde, MBBCh, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IB and beyond non–small cell lung cancer (NSCLC).

The Oncology Brothers and Isabel Preeshagul, DO, MBS, share clinical insights on later-line treatment practices for patients with metastatic non–small cell lung cancer.

Isabel Preeshagul, DO, MBS, and the Oncology Brothers discuss the treatment of patients with NSCLC and actionable mutations following progression on first-line therapy.

Medical oncologists discuss the role of dual checkpoint inhibitors with chemotherapy in the treatment of patients with metastatic non–small cell lung cancer.

Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for newly diagnosed patients with metastatic non–small cell lung cancer (NSCLC) and no actionable mutations.

Balazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.

The Oncology Brothers and Balazs Halmos, MD, provide clinical insights on therapeutic options for patients with NSCLC with rare mutations, including ROS1, BRAF V600E, and NTRK.